# Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies

> **NCT05206045** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 700 (estimated)

## Conditions studied

- Sezary Syndrome
- Cutaneous T Lymphoma

## Interventions

- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT05206045
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206045, "Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05206045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*